Overview

Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome

Status:
Terminated

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic syndrome who do not respond adequately to amlodipine monotherapy.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

Amlodipine
Ramipril